Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 218

1.

Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-α therapy.

Iannone F, Fanizzi R, Scioscia C, Anelli MG, Lapadula G.

Scand J Rheumatol. 2013;42(1):41-4. doi: 10.3109/03009742.2012.715186. Epub 2012 Sep 20.

PMID:
22991950
2.

Remission in psoriatic arthritis: is it possible and how can it be predicted?

Saber TP, Ng CT, Renard G, Lynch BM, Pontifex E, Walsh CA, Grier A, Molloy M, Bresnihan B, Fitzgerald O, Fearon U, Veale DJ.

Arthritis Res Ther. 2010;12(3):R94. doi: 10.1186/ar3021. Epub 2010 May 18.

3.

Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine.

Gremese E, Carletto A, Padovan M, Atzeni F, Raffeiner B, Giardina AR, Favalli EG, Erre GL, Gorla R, Galeazzi M, Foti R, Cantini F, Salvarani C, Olivieri I, Lapadula G, Ferraccioli G; Gruppo Italiano di Studio sulle Early Arthritis (GISEA).

Arthritis Care Res (Hoboken). 2013 Jan;65(1):94-100. doi: 10.1002/acr.21768.

4.

Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA.

Iannone F, Lopriore S, Bucci R, Scioscia C, Anelli MG, Notarnicola A, Lapadula G.

Scand J Rheumatol. 2015 May;44(3):192-9. doi: 10.3109/03009742.2014.962081. Epub 2015 Jan 7.

PMID:
25564882
5.

Dosage adjustment of anti-tumor necrosis factor-α inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice.

Paccou J, Baclé-Boutry MA, Solau-Gervais E, Bele-Philippe P, Flipo RM.

J Rheumatol. 2012 Jul;39(7):1418-23. doi: 10.3899/jrheum.111337. Epub 2012 Jun 15.

PMID:
22707611
6.

Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.

Arends S, Brouwer E, van der Veer E, Groen H, Leijsma MK, Houtman PM, Th A Jansen TL, Kallenberg CG, Spoorenberg A.

Arthritis Res Ther. 2011 Jun 20;13(3):R94. doi: 10.1186/ar3369.

8.

Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study.

Mancarella L, Bobbio-Pallavicini F, Ceccarelli F, Falappone PC, Ferrante A, Malesci D, Massara A, Nacci F, Secchi ME, Manganelli S, Salaffi F, Bambara ML, Bombardieri S, Cutolo M, Ferri C, Galeazzi M, Gerli R, Giacomelli R, Grassi W, Lapadula G, Cerinic MM, Montecucco C, Trotta F, Triolo G, Valentini G, Valesini G, Ferraccioli GF; GISEA group.

J Rheumatol. 2007 Aug;34(8):1670-3. Epub 2007 Jul 1. Erratum in: J Rheumatol. 2007 Sep;34(9):1947.

PMID:
17611987
9.

Etanercept and adalimumab treatment patterns in psoriatic arthritis patients enrolled in a commercial health plan.

Chastek B, Fox KM, Watson C, Gandra SR.

Adv Ther. 2012 Aug;29(8):691-7. doi: 10.1007/s12325-012-0039-3. Epub 2012 Aug 16.

PMID:
22903239
10.

Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.

Hyrich KL, Watson KD, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register.

Rheumatology (Oxford). 2006 Dec;45(12):1558-65. Epub 2006 May 16.

PMID:
16705046
11.
12.

Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study.

Saougou I, Markatseli TE, Papagoras C, Voulgari PV, Alamanos Y, Drosos AA.

Semin Arthritis Rheum. 2011 Apr;40(5):398-406. doi: 10.1016/j.semarthrit.2010.07.004. Epub 2010 Sep 16.

PMID:
20843542
13.

Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register.

Saad AA, Ashcroft DM, Watson KD, Hyrich KL, Noyce PR, Symmons DP; British Society for Rheumatology Biologics Register.

Arthritis Res Ther. 2009;11(2):R52. doi: 10.1186/ar2670. Epub 2009 Apr 8.

14.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

15.

Influence on effectiveness of early treatment with anti-TNF therapy in rheumatoid arthritis.

Escudero-Vilaplana V, Ramírez-Herraiz E, Trovato-López N, Alañón-Plaza E, Bellini MJ, Herranz-Alonso A, Bellón-Cano JM, Morell-Baladrón A, Sanjurjo-Sáez M.

J Pharm Pharm Sci. 2012;15(3):355-60.

16.

Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data.

Delaunay C, Farrenq V, Marini-Portugal A, Cohen JD, Chevalier X, Claudepierre P.

J Rheumatol. 2005 Nov;32(11):2183-5.

PMID:
16265699
17.

The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study.

Fagerli KM, Lie E, van der Heijde D, Heiberg MS, Lexberg AS, Rødevand E, Kalstad S, Mikkelsen K, Kvien TK.

Ann Rheum Dis. 2014 Jan;73(1):132-7. doi: 10.1136/annrheumdis-2012-202347. Epub 2013 Jan 3.

PMID:
23291385
18.

TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.

Tobin AM, Kirby B.

BioDrugs. 2005;19(1):47-57. Review.

PMID:
15691217
19.

Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity.

Krieckaert CL, Jamnitski A, Nurmohamed MT, Kostense PJ, Boers M, Wolbink G.

Arthritis Rheum. 2012 Dec;64(12):3850-5. doi: 10.1002/art.34680.

20.

The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study.

Heiberg MS, Kaufmann C, Rødevand E, Mikkelsen K, Koldingsnes W, Mowinckel P, Kvien TK.

Ann Rheum Dis. 2007 Aug;66(8):1038-42. Epub 2007 Jan 9.

Supplemental Content

Support Center